Tango Therapeutics, Inc. (NASDAQ:TNGX)
| Market Cap | 3.96B+187.9% |
| Revenue (ttm) | 53.81M+121.5% |
| Net Income | -123.72M+15.0% |
| EPS | -0.85+35.6% |
| Shares Out | 162.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,413,380 |
| Open | 24.92 |
| Previous Close | 24.92 |
| Day's Range | 23.70 - 24.92 |
| 52-Week Range | 6.69 - 34.39 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 45.91(+88.93%) |
| Earnings Date | Nov 3, 2026 |
Tango Therapeutics, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About TNGX
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TNGX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TNGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TNGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TNGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TNGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TNGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TNGX
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $106.00M |
| VTIVanguard Morningstar Total Stock Market ETF | $100.62M |
| IWMiShares Russell 2000 ETF | $88.69M |
| VXFVanguard Extended Market ETF | $32.84M |
| IWOiShares Russell 2000 Growth ETF | $32.71M |
| IBBiShares Biotechnology ETF | $25.74M |
Estimated from each fund’s disclosed top holdings × AUM
TNGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TNGX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score